Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study
Miwa Haranaka, Kazumi Suzukawa, Michael A. Pratta, Yan‐ou Yang et al.
Citations
1 citations
Journal
Clinical Drug Investigation
Topics
Immune Cell Function and Interaction
Field-Weighted Citation Impact (FWCI)
0.80
article
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study
Miwa Haranaka, Kazumi Suzukawa, Michael A. Pratta, Yan‐ou Yang, Hongfei Li, Kenzo Kinami
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical Drug InvestigationVol. 45(6)
Institutions
Quantitative BioSciences (US), SOUSEIKAI Global Clinical Research Center (JP), Incyte (United States) (US)